Evidence map›Paper›PMID 31056665›Full record

ArticleBrain : a journal of neurology2019

Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Elizabeth Cotzomi, Panos Stathopoulos, Casey S Lee, Alanna M Ritchie, John N Soltys, Fabien R Delmotte, Tyler Oe, Joel Sng, Ruoyi Jiang, Anthony K Ma and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 107 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Advances in the treatment of neuromyelitis optic spectrum disorder.Therapeutic advances in neurological disorders · 2025
    Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Elizabeth CotzomiDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Panos StathopoulosDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Casey S LeeDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Alanna M RitchieDepartments of Neurology and Ophthalmology and Neuroscience Program, University of Colorado, Denver, CO, USA.
John N SoltysDepartments of Neurology and Ophthalmology and Neuroscience Program, University of Colorado, Denver, CO, USA.
Fabien R DelmotteDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Tyler OeDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Joel SngDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Ruoyi JiangDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Anthony K MaDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Jason A Vander HeidenDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Steven H KleinsteinDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Michael LevyDepartment of Neurology, Johns Hopkins, School of Medicine, Baltimore, MD, USA.
Jeffrey L BennettDepartments of Neurology and Ophthalmology and Neuroscience Program, University of Colorado, Denver, CO, USA.
Eric MeffreDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Kevin C O'ConnorDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Yale University · USUniversity of Colorado Denver · USJohns Hopkins University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Autoimmunity Center of Excellence Clinical Research ProgramUM1AI110498 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOFSY, DAVID · 2014 to 2019
$31.4M
Regulation of IgA class switching in the intestinal mucosaP01AI061093 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CUNNINGHAM-RUNDLES, CHARLOTTE · 2004 to 2021
$29.8M
Medical Scientist Training ProgramT32GM008497 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI WILSON, CARA C. · 1993 to 2022
$15.2M
Mechanisms of autoimmunity in myasthenia gravisR01AI114780 · NIAID · YALE UNIVERSITY · PI Kevin C O'Connor · 2016 to 2026
$4.7M
Loss of B Cell Tolerance in Rheumatoid ArthritisR01AI071087 · NIAID · YALE UNIVERSITY · PI MEFFRE, ERIC · 2006 to 2016
$4.3M
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis OpticaR01EY022936 · NEI · UNIVERSITY OF COLORADO DENVER · PI BENNETT, JEFFREY L · 2013 to 2022
$3.8M
COMPUTATIONAL TOOLS FOR THE ANALYSIS OF HIGH-THROUGHPUT IMMUNOGLOBULIN SEQUENCING EXPERIMENTSR01AI104739 · NIAID · YALE UNIVERSITY · PI KLEINSTEIN, STEVEN H. · 2014 to 2022
$3.6M
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis OpticaR01AI130548 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LEVY, MICHAEL · 2018 to 2022
$2.0M
Mechanisms of autoantibody production in myasthenia gravisR56AI114780 · NIAID · YALE UNIVERSITY · PI O'CONNOR, KEVIN C · 2015 to 2015
$416k
NCATS NIH HHS UL1 TR001863NEI NIH HHS R01 EY022936NIAID NIH HHS P01 AI061093NIAID NIH HHS R01 AI071087NIAID NIH HHS R01 AI104739NIAID NIH HHS R01 AI114780NIAID NIH HHS R01 AI130548NIAID NIH HHS R56 AI114780NIAID NIH HHS UM1 AI110498NIGMS NIH HHS T32 GM008497
6 · The paper itself

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) constitute rare autoimmune disorders of the CNS that are primarily characterized by severe inflammation of the spinal cord and optic nerve. Approximately 75% of NMOSD patients harbour circulating pathogenic autoantibodies targeting the aquaporin-4 water channel (AQP4). The source of these autoantibodies remains unclear, but parallels between NMOSD and other autoantibody-mediated diseases posit compromised B cell tolerance checkpoints as common underlying and contributing factors. Using a well established assay, we assessed tolerance fidelity by creating recombinant antibodies from B cell populations directly downstream of each checkpoint and testing them for polyreactivity and autoreactivity. We examined a total of 863 recombinant antibodies. Those derived from three anti-AQP4-IgG seropositive NMOSD patients (n = 130) were compared to 733 antibodies from 15 healthy donors. We found significantly higher frequencies of poly- and autoreactive new emigrant/transitional and mature naïve B cells in NMOSD patients compared to healthy donors (P-values < 0.003), thereby identifying defects in both central and peripheral B cell tolerance checkpoints in these patients. We next explored whether pathogenic NMOSD anti-AQP4 autoantibodies can originate from the pool of poly- and autoreactive clones that populate the naïve B cell compartment of NMOSD patients. Six human anti-AQP4 autoantibodies that acquired somatic mutations were reverted back to their unmutated germline precursors, which were tested for both binding to AQP4 and poly- or autoreactivity. While the affinity of mature autoantibodies against AQP4 ranged from modest to strong (Kd 15.2-559 nM), none of the germline revertants displayed any detectable binding to AQP4, revealing that somatic hypermutation is required for the generation of anti-AQP4 autoantibodies. However, two (33.3%) germline autoantibody revertants were polyreactive and four (66.7%) were autoreactive, suggesting that pathogenic anti-AQP4 autoantibodies can originate from the pool of autoreactive naïve B cells, which develops as a consequence of impaired early B cell tolerance checkpoints in NMOSD patients.

Indexed as

AdultAquaporin 4AutoantibodiesB-LymphocytesFemaleHumansMaleMiddle AgedNeuromyelitis OpticaOptic NerveAquaporin 4AutoantibodiesAQP4autoantibodiesB cellsneuromyelitis optica spectrum disorder (NMOSD)tolerance

Identifiers

PMID31056665
PMCPMC6536857
OpenAlexW2944646085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.